Genetically Modified Lactococcus lactis Hypersecreting IL‐1Ra Improves Glucose Metabolism and Modulates the Gut Microbiota in an Obese Mouse Model
Journal of Diabetes Research · 2026
DOI: 10.1155/jdr/6006491 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Research, 2026. Verfasst von Masahiro Yoda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medicine, Science and Technology, Shinshu University, Nagano, Japan, shinshu-u.ac.jp. Hauptthemen laut MEDLINE: Interleukin 1 Receptor Antagonist Protein, Obesity, Lactococcus lactis, Gastrointestinal Microbiome. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder and typically develops later in life due to systemic dysfunction in metabolic homeostasis and various factors related to β ‐cell inflammation. Interestingly, recent studies have proposed that intra‐islet expression of inflammatory cytokines, particularly interleukin (IL)‐1 β , contributes to the pathogenesis of T2DM and have shown that blockade of IL‐1 β signaling improves glycemia and β ‐cell secretory function. We recently successfully constructed a genetically modified lactic acid bacteria (gmLAB) strain that hypersecretes recombinant mouse IL‐1 receptor antagonist (rmIL‐1Ra), that is, NZ‐IL1Ra. In this study, we investigated how NZ‐IL1Ra affects glucose metabolism using a mouse pancreatic β ‐cell line and diet‐induced obese mouse model. We found that rmIL‐1Ra purified from NZ‐IL1Ra suppresses the expression of mouse pancreatic β ‐cell genes related to inflammation. In addition, the results of oral glucose tolerance tests revealed that administration of NZ‐IL1Ra improves glucose metabolism, but the extent depends on the route of administration. Finally, microbiota analyses revealed increases in the abundances of two genera of Lachnospiraceae. These microbiota changes might also affect glucose metabolism in mice. Taken together, our results suggest that administration of NZ‐IL1Ra may be a useful tool for improving glucose metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Medicine, Science and Technology, Shinshu University, Nagano, Japan, shinshu-u.ac.jp.
- Department of Agriculture, Graduate School of Science and Technology, Shinshu University, Nagano, Japan, shinshu-u.ac.jp.
- Institute for Aqua Regeneration, Shinshu University, Nagano, Japan, shinshu-u.ac.jp.
- Food and Feed Immunology Group, Laboratory of Animal Food Function, Graduate School of Agricultural Science, Tohoku University, Sendai, Miyagi, Japan, tohoku.ac.jp.
- Institute for Biomedical Sciences, Shinshu University, Nagano, Japan, shinshu-u.ac.jp.
- Department of Medical Research on Prebiotics and Probiotics, Fujita Health University, Toyoake, Aichi, Japan, fujita-hu.ac.jp.
ORCID-Profile: Takeshi Shimosato
Zitieren
APA
Yoda, M., Nomura, N., Yoda, S., Kagotani, M., Murakami, A., Namai, F., Fujii, T., Tochio, T., Sato, T., & Shimosato, T. (2026). Genetically Modified Lactococcus lactis Hypersecreting IL‐1Ra Improves Glucose Metabolism and Modulates the Gut Microbiota in an Obese Mouse Model. Journal of Diabetes Research. https://doi.org/10.1155/jdr/6006491
Vancouver
Yoda M, Nomura N, Yoda S, Kagotani M, Murakami A, Namai F, et al. Genetically Modified Lactococcus lactis Hypersecreting IL‐1Ra Improves Glucose Metabolism and Modulates the Gut Microbiota in an Obese Mouse Model. Journal of Diabetes Research. 2026. doi:10.1155/jdr/6006491
BibTeX
@article{Yoda2026,
author = {Yoda, Masahiro and Nomura, Natsumi and Yoda, Shoko and Kagotani, Mao and Murakami, Aito and Namai, Fu and Fujii, Tadashi and Tochio, Takumi and Sato, Takashi and Shimosato, Takeshi},
title = {Genetically Modified Lactococcus lactis Hypersecreting IL‐1Ra Improves Glucose Metabolism and Modulates the Gut Microbiota in an Obese Mouse Model},
journal = {Journal of Diabetes Research},
year = {2026},
doi = {10.1155/jdr/6006491}
}
EUVIMED